Vineet Laboratories Limited (VINEETLAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vineet Laboratories Limited (VINEETLAB) has a cash flow conversion efficiency ratio of 0.035x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs12.24 Million ≈ $132.37K USD) by net assets (Rs348.52 Million ≈ $3.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vineet Laboratories Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Vineet Laboratories Limited - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Vineet Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vineet Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vineet Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Corazon Mining Ltd
AU:CZN
|
-0.019x |
|
Thor Energy Plc
AU:THR
|
-0.059x |
|
ONCODES.PREC.MED. EO-34
F:ZR8
|
N/A |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
-11.870x |
|
Readcloud Ltd
AU:RCL
|
-0.153x |
|
CYL Corporation Bhd
KLSE:7157
|
0.081x |
|
Torr Metals Inc
V:TMET
|
-0.067x |
|
Iceni Gold Ltd
AU:ICL
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Vineet Laboratories Limited (2020–2025)
The table below shows the annual cash flow conversion efficiency of Vineet Laboratories Limited from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Vineet Laboratories Limited stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs146.48 Million ≈ $1.58 Million |
Rs114.91 Million ≈ $1.24 Million |
0.784x | +512.06% |
| 2024-03-31 | Rs347.24 Million ≈ $3.76 Million |
Rs-66.11 Million ≈ $-714.94K |
-0.190x | +33.31% |
| 2023-03-31 | Rs336.83 Million ≈ $3.64 Million |
Rs-96.16 Million ≈ $-1.04 Million |
-0.285x | -222.92% |
| 2022-03-31 | Rs332.18 Million ≈ $3.59 Million |
Rs77.15 Million ≈ $834.34K |
0.232x | +170.95% |
| 2021-03-31 | Rs266.15 Million ≈ $2.88 Million |
Rs-87.12 Million ≈ $-942.20K |
-0.327x | -4160.69% |
| 2020-03-31 | Rs3.99 Million ≈ $43.14K |
Rs-30.65K ≈ $-331.44 |
-0.008x | -- |
About Vineet Laboratories Limited
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl… Read more